Awaiting development: Guidance and quality standards

Showing 131 to 140 of 283

Guidance and quality standards awaiting development
Title	Type
Icotrokinra for treating moderate to severe plaque psoriasis in people 12 years and over [ID6579]	Technology appraisal guidance
Imetelstat for treating intermediate-2 or high-risk relapsed or refractory myelofibrosis after a JAK inhibitor [TSID8376]	Technology appraisal guidance
Inclacumab for preventing recurrent vaso-occlusive crises in sickle cell disease in people 16 years and over [ID6551]	Technology appraisal guidance
Inclisiran for treating familial hypercholesterolaemia and elevated low density lipoprotein cholesterol in people 12 to 17 years [TSID12129]	Technology appraisal guidance
Inebilizumab for treating generalised myasthenia gravis [ID6587] [TSID12110]	Technology appraisal guidance
Inebilizumab for treating immunoglobulin G4-related disease [TSID12107]	Technology appraisal guidance
Inolimomab (Leukotac) for acute Graft versus host disease (aGvHD) after Allo-HSCT [ID3923]	Technology appraisal guidance
Insulin efsitora alfa for treating type 2 diabetes in people on daily insulin injections [ID6499]	Technology appraisal guidance
Invimestrocel for treating acute ischaemic stroke within 18 to 36 hours of onset [TSID10190]	Technology appraisal guidance
Irbesartan–propagermanium for treating focal segmental glomerulosclerosis in people 12 years and over having an angiotensin II receptor blocker [ID6469]	Technology appraisal guidance